Hepion Pharmaceuticals, Inc. stock is up 32.61% since 30 days ago. The next earnings date is Apr 8, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 40% of the previous 10 February’s closed higher than January.
Hepion Pharmaceuticals, Inc. focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease.
Unlock Exclusive Market Insights! Receive timely updates on market developments. Sign up & stay informed!